Spyre Therapeutics, Inc.
SYRE
Rangering i aksjer
#2337
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical... Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD. Furthermore, Spyre Therapeutics is advancing SPY002, another human monoclonal antibody that aims to interact with tumor necrosis factor-like ligand 1A (TL1A). A synergistic approach is also being explored with SPY120, a compound that merges the anti-a4ß7 action of SPY001 with the anti-TL1A activity of SPY002. All these programs are currently undergoing preclinical evaluation. Beyond these, the company's early-stage portfolio encompasses several additional promising candidates: SPY003, an anti-IL-23 monoclonal antibody; SPY004, a monoclonal antibody with a novel mechanism of action; SPY130, which combines anti-a4ß7 and anti-IL-23 antibodies; and SPY230, a dual antibody therapy featuring anti-TL1A and anti-IL-23 components. Originally incorporated in 2013, the organization was previously known as Aeglea BioTherapeutics, Inc., before rebranding to Spyre Therapeutics, Inc. in November 2023. Its headquarters are located in Waltham, Massachusetts.
Aksjekurs
$91.87
Sist synkronisert: 2026-10-20
Markedsverdi
$8.48B
Endring (1 dag)
8.44%
Endring (1 år)
295.14%
Land
US
Handel Spyre Therapeutics, Inc. (SYRE)
Kategori
Healthcare
Antall utestående aksjer for Spyre Therapeutics, Inc. (SYRE)
Antall utestående aksjer per June 2026: 84.73M
Ifølge Spyre Therapeutics, Inc. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 84.73M. Ved slutten av December 2023 hadde selskapet 6.90M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Spyre Therapeutics, Inc. (SYRE) fra 2014 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 84.73M | 80.17% |
| 2024 | 47.03M | 581.85% |
| 2023 | 6.90M | 104.59% |
| 2022 | 3.37M | 28.19% |
| 2021 | 2.63M | 23.18% |
| 2020 | 2.13M | 67.05% |
| 2019 | 1.28M | 53.44% |
| 2018 | 832.90K | 37.64% |
| 2017 | 605.13K | 54.50% |
| 2016 | 391.67K | -14.33% |
| 2015 | 457.19K | -16.45% |
| 2014 | 547.19K | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | 199.66% |
US
|
|
| 396.00M | 367.37% |
US
|
|
| 478.91M | 465.23% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -26.61% |
NL
|
